Zejing Pharmaceutical (688266.SH): ZG005 has shown significant efficacy and good safety in late-stage cervical cancer patients.

Zejing Pharmaceutical (688266.SH) announced that multiple clinical research results of the company's new antibody drugs have been selected for oral or poster presentations at the 27th Chinese Clinical Oncology Conference and the 2024 CSCO Academic Annual Meeting. Among them, the preliminary results of the phase I/II clinical trial of the bispecific antibody ZG005 targeting TIGIT/PD-1 in advanced solid tumor patients (protocol number: ZG005-001) have been selected for oral presentation in the session on the research and development of new antitumor drugs and technologies. Preliminary data shows that ZG005 demonstrated good tolerance, safety, and antitumor efficacy in the dose escalation and expansion studies of the phase I/II trial. Particularly in advanced cervical cancer patients, the efficacy of treatment with ZG005 was significant with good safety profile.